These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 9452341

  • 1. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections.
    Sankhla C, Jankovic J, Duane D.
    Mov Disord; 1998 Jan; 13(1):150-4. PubMed ID: 9452341
    [Abstract] [Full Text] [Related]

  • 2. Long-term botulinum toxin efficacy, safety, and immunogenicity.
    Mejia NI, Vuong KD, Jankovic J.
    Mov Disord; 2005 May; 20(5):592-7. PubMed ID: 15645481
    [Abstract] [Full Text] [Related]

  • 3. Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients.
    Greene PE, Fahn S.
    Mov Disord; 1996 Mar; 11(2):181-4. PubMed ID: 8684389
    [Abstract] [Full Text] [Related]

  • 4. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD, Cullis PA, O'Brien CF, Koller M, Villegas TP, Wallace JD.
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Botulinum toxin A--injection for cervical dystonia.
    Bhaumik S, Behari M.
    J Assoc Physicians India; 1999 Mar; 47(3):267-70. PubMed ID: 10999117
    [Abstract] [Full Text] [Related]

  • 11. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A.
    Atassi MZ, Jankovic J, Dolimbek BZ.
    Neurology; 2008 Sep 23; 71(13):1040; author reply 1040-1. PubMed ID: 18809844
    [No Abstract] [Full Text] [Related]

  • 12. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study.
    Naumann M, Lowe NJ, Kumar CR, Hamm H, Hyperhidrosis Clinical Investigators Group.
    Arch Dermatol; 2003 Jun 23; 139(6):731-6. PubMed ID: 12810503
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor.
    Wissel J, Masuhr F, Schelosky L, Ebersbach G, Poewe W.
    Mov Disord; 1997 Sep 23; 12(5):722-6. PubMed ID: 9380055
    [Abstract] [Full Text] [Related]

  • 16. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.
    Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, Liu J, Brin MF.
    Clin Ther; 2007 Apr 23; 29(4):683-90. PubMed ID: 17617291
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Fast voluntary neck movements in patients with cervical dystonia: a kinematic study before and after therapy with botulinum toxin type A.
    Gregori B, Agostino R, Bologna M, Dinapoli L, Colosimo C, Accornero N, Berardelli A.
    Clin Neurophysiol; 2008 Feb 23; 119(2):273-80. PubMed ID: 18063411
    [Abstract] [Full Text] [Related]

  • 19. Development of resistance to botulinum toxin type A in patients with torticollis.
    Greene P, Fahn S, Diamond B.
    Mov Disord; 1994 Mar 23; 9(2):213-7. PubMed ID: 8196686
    [Abstract] [Full Text] [Related]

  • 20. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.
    Greene PE, Fahn S.
    Mov Disord; 1993 Oct 23; 8(4):479-83. PubMed ID: 8232357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.